Evidence map›Paper›PMID 40298449›Full record

ArticlemBio2025

Role of glucuronoxylomannan and steryl glucosides in protecting against cryptococcosis.

Gabriel Soares Matos, Samyr M Querobino, Veronica S Brauer, Luna S Joffe, Nivea Pereira de Sa, Caroline Mota Fernandes, Deveney DaSilva, Vanessa A da Silva, Marinaldo Pacífico Cavalcanti Neto, Tyler Normile and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Gabriel Soares Matos *Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Samyr M Querobino *Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Veronica S BrauerDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Luna S JoffeDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Nivea Pereira de SaDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Caroline Mota FernandesDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Deveney DaSilvaDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Vanessa A da SilvaDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Marinaldo Pacífico Cavalcanti NetoDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Tyler NormileDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Hengwei ZhuDepartment of Chemistry, Stony Brook University, Stony Brook, New York, USA.
Surita R BhatiaDepartment of Chemistry, Stony Brook University, Stony Brook, New York, USA.
Li TanComplex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.
Parastoo AzadiComplex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.
Christian HeissComplex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.
Tamara L DoeringDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-5179-7393
Maurizio Del PoetaDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.ORCID 0000-0001-8418-3120

Funding

New antifungals targeting the synthesis of fungal sphingolipidsR01AI116420 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI Maurizio Del Poeta · 2016 to 2026
$7.6M
Lipid-mediated fungal pathogenesisR01AI125770 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI DEL POETA, MAURIZIO · 2016 to 2025
$6.2M
National Glycoscience Resource- CCRC Service and Training - NGlycoR@CCRCR24GM137782 · NIGMS · UNIVERSITY OF GEORGIA · PI Parastoo Azadi · 2020 to 2026
$5.2M
CRYPTOCOCCAL GLYCAN SYNTHESISR01AI135012 · NIAID · WASHINGTON UNIVERSITY · PI DOERING, TAMARA L · 2018 to 2022
$2.5M
Sphingosine kinase and cryptococcal granulomaR01AI184929 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI Maurizio Del Poeta · 2025 to 2026
$1.5M
BLRD VA I01 BX002624BLRD VA IK6 BX005386National Institute of Allergy and Infectious Diseases AI116420National Institute of Allergy and Infectious Diseases AI125770National Institute of Allergy and Infectious Diseases AI135012National Institute of Allergy and Infectious Diseases AI184929National Science Foundation DMR-1905547National Science Foundation DMR-1933525NIAID NIH HHS R01 AI116420NIAID NIH HHS R01 AI125770NIAID NIH HHS R01 AI135012NIAID NIH HHS R01 AI184929NIGMS NIH HHS GM137782NIGMS NIH HHS R24 GM137782U.S. Department of Energy DE-SC0015662U.S. Department of Veterans Affairs I01BX002624
6 · The paper itself

Abstract

The development of vaccines for fungal diseases, including cryptococcosis, is an emergent line of research and development. In previous studies, we showed that a

Indexed as

CryptococcosisCryptococcus neoformansGlucosidesPolysaccharidesAnimalsFemaleFungal VaccinesGene DeletionGlucosidasesMacrophagesMaleMiceMutationNucleotide Transport ProteinsPhagocytosisReceptors, Antigen, T-Cell, gamma-deltaFungal VaccinesGlucosidasesGlucosidesglucuronoxylomannanNucleotide Transport ProteinsPolysaccharidesReceptors, Antigen, T-Cell, gamma-deltaCryptococcus neoformansfungal infectionglucuronic acidglucuronoxylomannanimmunitymannosesteryl glucosidesvaccinexylose

Identifiers

PMID40298449
PMCPMC12153286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.